Human heart, computer artwork. Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.
Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...
Background Pharmacotherapy combinations have been shown to improve survival and reduce hospitalisations in adults with ...
What you need to know The prevalence of heart failure across Europe is estimated to be 1-2% of adults.1 In the UK, this places a substantial burden on patients and healthcare resources, including ...
Credit: Getty Images. The approval was based on data from the phase 3 EMPEROR-Reduced trial. The Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) to reduce the risk of ...
"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...
Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or hospitalization for heart failure by 20% in heart failure ...
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...
Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...
Human heart, computer artwork. Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results